Researchers from UMN Pharma Inc. presented pharmacological study results at the annual Digestive Disease Week conference demonstrating the impact of UMN-02, a specific 5HT-2A receptor antagonist, on choline-deficient ethionine-supplemented (CDE) diet-induced necrotizing acute pancreatitis in mice. This presentation showed that UMN-02 ameliorated severe necrotizing acute pancreatitis in mice by inhibiting key inflammatory responses. Based on these experimental results, we believe that UMN-02 could serve as a novel therapeutic for the treatment of acute pancreatitis. UMN-02 is a highly specific 5HT-2A receptor antagonist being developed by UMN Pharma Inc. for the treatment of acute pancreatitis. Further details about our presentation can be found in the conference proceedings from the DIGESTIVE DESEASE WEEK 2008.